-
ESMO 2024 | Dr. Wei Yu: Advances in Perioperative Immunotherapy and Combined Immunotherapy for Muscle-Invasive Urothelial Carcinoma Patients
Research has shown that nearly 50% of patients with muscle-invasive urothelial carcinoma (MIUC) will experience recurrence with distant metastases. Therefore, exploring perioperative treatments for muscle-invasive bladder cancer (MIBC) is crucial to improving patient outcomes. The 2024 European Society for Medical Oncology (ESMO) Congress, held from September 13 to 17 in Barcelona, Spain, highlighted several advances…
-
Dr. Hua Wang: New Approaches in Marginal Zone Lymphoma Treatment – Rethinking Chemotherapy-Free and Combination Strategies丨The 5th Tianjin International Lymphoma Symposium
From September 6-8, 2024, the 5th Tianjin International Lymphoma Symposium was successfully held. The conference featured twelve specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Hua Wang from the Sun Yat-sen University Cancer Center to review…
-
Mesenchymal Stem Cell-Derived Exosomes Alleviate Liver Fibrosis
Identification and Characterization of UC-MSCs and UC-MSCs-Exo The researchers isolated UC-MSCs from human umbilical cord tissue. These cells were spindle-shaped, adherent, and capable of differentiating into adipocytes, osteoblasts, and chondrocytes.…
-
ESCMID-EUCIC | Guidelines on Preoperative Decolonization and Targeted Prevention for MDR Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus (MRSA) Question 1.1: Should patients be screened for MRSA before surgery? Recommendation: Screening for methicillin-sensitive Staphylococcus aureus (MSSA) and MRSA prior to elective cardiac and orthopedic surgeries…
-
CUA 2024丨Dr. Shancheng Ren: “Super Veil Technique” in Extraperitoneal Single-Port Robotic Radical Prostatectomy Meets Patient Needs, Changhai Urology Continues to Tackle AI, Surgical Strategy, and Other Cutting-Edge Challenges
Younger, low-risk prostate cancer patients often prioritize quality of life, particularly urinary control and sexual function, leading to ongoing clinical exploration for treatment strategies that meet these demands. From September 19 to 22, 2024, the 31st Urology Academic Conference was held at the National Convention Center in Tianjin. After the conference, Urology Frontier invited Dr.…
-
CSCO 2024 | Pioneers in Melanoma Care Chart China’s Path to Personalized Therapies
Although melanoma has a relatively low incidence among malignant tumors, its hidden onset and high malignancy make it a formidable disease. In recent years, targeted and immunotherapy treatments for solid tumors have developed rapidly, many of which began with melanoma and later extended to other cancers. However, there are significant biological differences between melanoma in…
-
CSCO 2024 | Pioneering Cellular Therapies and Precision Strategies in Ovarian Cancer
The 2024 CSCO Ovarian Cancer Session covered various topics, including surgical treatment for ovarian cancer, drug therapy for advanced-stage patients, and data from novel drug research. Dr. Lingying Wu from the Cancer Hospital Chinese Academy of Medical Sciences chaired the session, where Dr. Oliver Dorigo from Stanford University delivered a report on “Cellular Therapy for…
-
Dr. Biyun Wang: Early Exploration and Future Prospects of the Novel ADC Drug GQ1005 in HER2-Low Breast Cancer and HER2-Positive Gastric Cancer
At the 2024 ESMO Conference, the Phase 1a/1b study of the novel drug GQ1005, led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center, was showcased as a poster presentation, garnering significant attention. This study not only confirmed the efficacy and safety of GQ1005 in HER2-low breast cancer and HER2-positive gastric cancer but also…
Connecting Medical Expertise through Media